Quanterix Presented Ultrasensitive Technology At Nfl Health And Safety Update & Interactive Head Health Showcase
Lexington, Mass. – Quanterix Corporation, a leader in the transformation to digital medicine with an ultrasensitive single molecule testing for the benefit of human health, yesterday participated in the NFL Health and Safety Update & Interactive Head Health Showcase at Super Bowl 50.
As a finalist of the GE/NFL Head Health Challenge I – a part of the Head Health Initiative, which is a collaboration between the NFL, GE and Under Armour – Quanterix showcased their ground-breaking single molecule detection technology and its ability to detect even the mildest of concussions through a simple blood test.
“GE and the NFL clearly recognize the pressing need to better understand and accurately diagnose mild traumatic brain injury, and we’re honored to be able to showcase how our Simoa technology is able to do just that,” said Kevin Hrusovsky, CEO and Executive Chairman, Quanterix. “Our technology is truly revolutionary as nobody thought that biomarkers associated with brain injury would be something you could find by conducting a simple blood test; however, we are able to not only detect these minute proteins but, for the first time, quantify the severity of the trauma. The applications for this technology are truly limitless and the opportunities that GE and the NFL have provided our Company are helping to fuel game-changing discoveries across the spectrum of human health, including the ability to detect cancer biomarkers at smaller concentrations than ever before. This, in turn, drives earlier detection and will eventually redefine remission for oncology.”
Members of the NFL medical community, including Betsy Nabel, M.D., NFL Chief Medical Advisor; Mitch Berger, M.D., NFL Head, Neck and Spine Committee; Professor and Chairman, Department of Neurological Surgery, University of California San Francisco; and Jeff Miller, NFL Senior Vice President of Health & Safety Policy, also provided an update on the league’s health and safety efforts.
To learn more about Simoa, please visit: www.quanterix.com.
Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: www.quanterix.com.
Nikki Festa & Caitlyn Keating
Share this page